AVITA Medical, Inc. 8-K

What Happened AVITA Medical announced that its Board appointed Cary Vance as President and Chief Executive Officer effective April 30, 2026; Vance will remain an executive member of the Board. At the same time the Board named Jan Stern Reed as Chair and ended the Lead Independent Director role she had held since October 2025. The company filed the 8‑K on May 1, 2026 and issued a press release on April 30, 2026.

Key Details

• Vance’s employment agreement (effective April 30, 2026) provides an initial base salary of $702,000 per year and a target annual bonus equal to 80% of base salary.
• Equity compensation: eligible for a grant split 50% RSUs / 50% stock options with an aggregate cash value of $2,529,000, plus an additional RSU award valued at $825,000. Awards vest over three years in equal annual installments; the first 1/3 vests immediately upon stockholder approval at the 2027 Annual Meeting.
• Severance if terminated without Cause or for Good Reason: prorated annual bonus, 18 months of base salary, and up to 18 months of COBRA reimbursement, subject to execution of a release.
• Vance stepped down from Audit, Nominating & Corporate Governance committees and as Chair of Human Capital & Compensation when he became Interim CEO in Oct 2025; he has served on the Board since April 2023.

Why It Matters This filing confirms a permanent CEO appointment and a change in board leadership, providing clarity on executive leadership and governance. The compensation package includes significant equity awards that require shareholder approval and will have dilution and accounting/expense implications once granted and vested. The severance and bonus terms define potential near‑term cash obligations under certain termination scenarios. Retail investors should note the timing of shareholder approval (2027 ASM) for the equity awards and monitor related proxy materials and future disclosures for more detail.